Barings’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-5,812
| Closed | -$298K | – | 187 |
|
|
2022
Q4 | $298K | Sell |
5,812
-654
| -10% | -$31.4K | 0.01% | 165 |
|
|
2022
Q3 | $283K | Sell |
6,466
-27,562
| -81% | -$1.34M | 0.01% | 162 |
|
|
2022
Q2 | $1.78M | Sell |
34,028
-7,237
| -18% | -$369K | 0.06% | 125 |
|
|
2022
Q1 | $2.14M | Sell |
41,265
-9,469
| -19% | -$491K | 0.06% | 135 |
|
|
2021
Q4 | $3M | Buy |
50,734
+2,609
| +5% | +$129K | 0.08% | 129 |
|
|
2021
Q3 | $2.07M | Buy |
48,125
+12,140
| +34% | +$538K | 0.05% | 151 |
|
|
2021
Q2 | $1.41M | Sell |
35,985
-2,912
| -7% | -$113K | 0.03% | 188 |
|
|
2021
Q1 | $1.41M | Sell |
38,897
-2,112
| -5% | -$75K | 0.03% | 192 |
|
|
2020
Q4 | $1.51M | Sell |
41,009
-221,055
| -84% | -$8.11M | 0.04% | 186 |
|
|
2020
Q3 | $9.13M | Buy |
262,064
+33,847
| +15% | +$1.19M | 0.21% | 82 |
|
|
2020
Q2 | $7.07M | Hold |
228,217
| – | – | 0.24% | 80 |
|
|
2020
Q1 | $7.07M | Buy |
228,217
+9,447
| +4% | +$322K | 0.24% | 80 |
|
|
2019
Q4 | $8.13M | Buy |
218,770
+28,182
| +15% | +$1M | 0.22% | 93 |
|
|
2019
Q3 | $6.5M | Buy |
190,588
+40
| +0% | +$1.46K | 0.15% | 136 |
|
|
2019
Q2 | $7.83M | Buy |
190,548
+4,220
| +2% | +$168K | 0.17% | 120 |
|
|
2019
Q1 | $7.51M | Sell |
186,328
-80,947
| -30% | -$3.24M | 0.17% | 102 |
|
|
2018
Q4 | $11.1M | Sell |
267,275
-289,180
| -52% | -$12M | 0.19% | 85 |
|
|
2018
Q3 | $23.3M | Buy |
556,455
+153,159
| +38% | +$5.9M | 0.33% | 53 |
|
|
2018
Q2 | $13.9M | Sell |
403,296
-17,610
| -4% | -$602K | 0.2% | 90 |
|
|
2018
Q1 | $14.2M | Buy |
420,906
+48,877
| +13% | +$1.68M | 0.2% | 81 |
|
|
2017
Q4 | $12.8M | Buy |
372,029
+69,171
| +23% | +$2.36M | 0.17% | 104 |
|
|
2017
Q3 | $10.3M | Buy |
302,858
+52,278
| +21% | +$1.68M | 0.18% | 84 |
|
|
2017
Q2 | $7.99M | Sell |
250,580
-185,420
| -43% | -$5.85M | 0.23% | 88 |
|
|
2017
Q1 | $14.2M | Buy |
436,000
+258,462
| +146% | +$8.15M | 0.16% | 111 |
|
|
2016
Q4 | $5.47M | Sell |
177,538
-146,082
| -45% | -$4.46M | 0.14% | 84 |
|
|
2016
Q3 | $10.4M | Sell |
323,620
-258,125
| -44% | -$8.63M | 0.27% | 37 |
|
|
2016
Q2 | $19.4M | Buy |
581,745
+171,064
| +42% | +$5.46M | 0.5% | 14 |
|
|
2016
Q1 | $11.5M | Sell |
410,681
-151,354
| -27% | -$4.32M | 0.31% | 40 |
|
|
2015
Q4 | $17.2M | Buy |
562,035
+78,101
| +16% | +$2.46M | 0.43% | 20 |
|
|
2015
Q3 | $14.4M | Sell |
483,934
-11,642
| -2% | -$373K | 0.36% | 34 |
|
|
2015
Q2 | $15.8M | Sell |
495,576
-87,904
| -15% | -$2.86M | 0.48% | 36 |
|
|
2015
Q1 | $19.3M | Sell |
583,480
-73,463
| -11% | -$2.34M | 0.44% | 22 |
|
|
2014
Q4 | $19.4M | Buy |
656,943
+2,424
| +0.4% | +$69.5K | 0.43% | 25 |
|
|
2014
Q3 | $18.4M | Sell |
654,519
-118,681
| -15% | -$3.33M | 0.4% | 28 |
|
|
2014
Q2 | $21.8M | Buy |
773,200
+30,777
| +4% | +$877K | 0.65% | 20 |
|
|
2014
Q1 | $22.6M | Sell |
742,423
-47,324
| -6% | -$1.41M | 0.71% | 18 |
|
|
2013
Q4 | $23M | Buy |
789,747
+128,166
| +19% | +$3.73M | 0.96% | 13 |
|
|
2013
Q3 | $18M | Sell |
661,581
-131,434
| -17% | -$3.58M | 0.77% | 20 |
|
|
2013
Q2 | $21.1M | Buy |
+793,015
| New | +$21.9M | 0.95% | 15 |
|
Other funds holding PFE
Barings's PFE Position: Q1 2023 in Review
Barings sold out of Pfizer (PFE) in Q1 2023, closing a stake of 5,812 shares — an estimated $298K sold.
Barings first reported a position in PFE in Q2 2013 and held it in 39 quarters. The position peaked at $23.3M in Q3 2018. 3,102 funds tracked by Wall St. Rank hold PFE as of Q1 2023.
- Barings reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
- Barings sold 5,812 Pfizer shares in Q1 2023, an estimated $298K.
- Barings first reported a position in Pfizer in Q2 2013 and held it in 39 quarters.
- Barings's Pfizer position peaked at $23.3M in Q3 2018.
- 3,102 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.
Based on Barings's 13F filing for Q1 2023, filed 9 May 2023.